Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity.
To determine if surfactant replacement treatment is associated with an increase in the prevalence of retinopathy of prematurity (ROP) we studied 76 preterm babies who were treated with porcine surfactant (Curosurf) for severe respiratory distress syndrome from 1985 to 1990. Babies were first examined by indirect ophthalmoscopy at the equivalent of 32 weeks post-menstrual age and subsequently at 2-week intervals until discharge from hospital. Findings were documented according to the International Classification of ROP. Sixty-two (82%) babies survived to discharge, 7 survivors were not examined due to transfer elsewhere. Acute ROP developed in 14 (29%) of the 49 babies examined (7 stage I, 4 stage II, 2 stage III, and 1 stage IV); one baby required cryotherapy. No baby of birthweight greater than 1,500 g developed ROP. The prevalence of ROP was similar to that reported for non-surfactant-treated very-low-birthweight babies. We conclude that Curosurf treatment does not increase the risk of acute ROP in surviving very-low-birthweight babies.
Tubman
T R
TR
Neonatal Intensive Care Unit, Royal Maternity Hospital, Belfast, UK.
Rankin
S J
SJ
Halliday
H L
HL
Johnston
S S
SS
D001688:Biological Products; D005260:Female; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D009017:Morbidity; D010100:Oxygen / Q000097:blood; D010743:Phospholipids; D011663:Pulmonary Surfactants / Q000009:adverse effects*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy / Q000401:mortality; D012178:Retinopathy of Prematurity / Q000209:etiology*
D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa; D010100:Oxygen